Drug Profile
SAR 445710
Alternative Names: Anti-human-PD-L1-IL-15 bispecific protein - Kadmon Corporation; Bi-functional anti-PD-L1/IL-15 fusion protein - Kadmon Corporation; KD-033; SAR-445710Latest Information Update: 24 Jan 2024
Price :
$50
*
At a glance
- Originator Takeda
- Developer Kadmon Holdings
- Class Antineoplastics; Immunoglobulin fusion proteins; Immunotherapies; Interleukins; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants; Interleukin 15 replacements; Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 11 Jan 2024 Kadmon terminates a phase I trial in Solid tumours (Late-stage disease, Metastatic disease) in USA (IV, Infusion), due to sponsor's decision (NCT04242147)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in USA (IV, Injection)
- 31 Mar 2023 Phase-I development in Solid-tumours is ongoing in USA